AZD-1208
AZD1208 is an orally bioavailable, highly selective PIM kinases inhibitor with single nanomolar potency against all three PIM kinases (IC50 of 0.4 nM, 5 nM, and 1.9 nM for Pim1, Pim2, and Pim3 in cell-free assays, respectively) and is used for treating AML.